Single-pill triple fixed dose combination therapy with single component drug monitoring in treatment-resistant hypertension: a pilot study.

CONCLUSION: Our results support the use of single-pill triple FDC therapy in combination with TDM for the management of patients with suspected treatment-resistant hypertension and further testing in clinical studies. PMID: 28828980 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/28828980?dopt=Abstract

Source: Current Vascular Pharmacology - August 21, 2017 Category: Drugs & Pharmacology Authors: Kreutz R, Scholze J, Douros A Tags: Curr Vasc Pharmacol Source Type: research

More News: Drugs & Pharmacology | Hydrochlorothiazide | Hypertension | Norvasc | Study